HC Wainwright Predicts Stronger Earnings for Biomea Fusion

Biomea Fusion, Inc. (NASDAQ:BMEA) – Analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of Biomea Fusion in a research note issued on Monday, June 23rd. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.66). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Biomea Fusion’s current full-year earnings is ($3.93) per share. HC Wainwright also issued estimates for Biomea Fusion’s Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.92) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.14) EPS and FY2028 earnings at ($2.27) EPS.

Biomea Fusion (NASDAQ:BMEA) last posted its earnings results on Monday, May 5th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.04.

Other equities analysts also recently issued reports about the stock. Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a report on Monday, March 24th. Barclays dropped their target price on shares of Biomea Fusion from $11.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, April 2nd. Piper Sandler began coverage on shares of Biomea Fusion in a report on Tuesday, June 3rd. They set an “overweight” rating and a $7.00 target price for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $16.00 price target on shares of Biomea Fusion in a research note on Tuesday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $21.40.

Biomea Fusion Trading Up 2.6%

NASDAQ:BMEA opened at $1.99 on Thursday. The firm has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $2.89. Biomea Fusion has a twelve month low of $1.29 and a twelve month high of $13.07. The company has a market capitalization of $74.76 million, a P/E ratio of -0.56 and a beta of -0.23.

Institutional Investors Weigh In On Biomea Fusion

Hedge funds have recently modified their holdings of the company. Maia Wealth LLC acquired a new stake in shares of Biomea Fusion in the fourth quarter worth approximately $62,000. PNC Financial Services Group Inc. boosted its position in shares of Biomea Fusion by 14.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 24,005 shares of the company’s stock worth $93,000 after acquiring an additional 3,005 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Biomea Fusion in the fourth quarter worth approximately $54,000. Virtu Financial LLC acquired a new stake in shares of Biomea Fusion in the fourth quarter worth approximately $103,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Biomea Fusion by 27.6% in the fourth quarter. JPMorgan Chase & Co. now owns 22,535 shares of the company’s stock worth $87,000 after acquiring an additional 4,868 shares during the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.

Biomea Fusion Company Profile

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.